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samples from asymptomatic subjects (34.3% [62/181] vs. 25.4%
[114/449]; p=0.03). Potential pathogens in symptomatic subjects
were more likely to be treated than were pathogens in asymp-
tomatic subjects (83.9% [52/62] vs. 26.3% [30/114]; p<0.0001).
Conclusions: The majority of surveillance BAL cultures were non-
diagnostic and the results rarely altered the management of
asymptomatic lung transplant recipients. Routine mycobacterial
culture and PCP staining were of particularly low yield.
32
Impact of Drug Interactions on Choice of Antifungal
Therapy in Treating IFI. A Case Report of Use of
Posaconazole to Treat Fusarium Soft Tissue Infection in a
Liver Transplant Patient on Sirolimus
Shariq Haider. McMaster University, Division of Infectious
Diseases, 3V42 1200 Main St West Hamilton Ontario Canada
Background: Fungal infections are the most common cause of cu-
taneous infections in solid organ transplant patients. We describe
a case of soft tissue infection of the toe caused by Fuasarium
chlamydosporum and Candida guilliermondii in a liver transplant
patient on sirolimus, and discuss the pharmacokinetic interactions
of sirolimus and the new triazoles and their impact on treatment
choices.
Case: A 57 year old male post liver transplant in 2005 for Budd
Chiari Syndrome on Sirolimus 2mg daily, cellcept 750mg po bid,
developed an invasive soft tissue infection of his 5th toe after
spending a few weeks at his cottage walking bare feet. He noted
marked swelling and purple discoloration of his 5th toe two weeks
after returning from his cottage in the summer of 2007 (Figure 1).
A biopsy of the toe was done and identified on culture Candida
guilliermondii and Fusarium chlamydosporum. Susceptibility test-
ing for both isolates was done (Table 1). Patient was treated with
posaconazole 400mg po bid for 6 months with complete resolu-
tion of infection. Sirolimus was dose adjusted to 1mg everyother
day due to significant incr. in AUC of Sirolimus through the CYP450
isoenzymes.
Figure 1
Table 1. Susceptibility profile
Candida guilliermondii
Fluconazole 2mg/L Susceptible
Itraconazole 0.25mg/L Susceptible
5-Flucytosine 0.03mg/L Susceptible
Amphotericin B 0.5 mg/L No interpretation
Voriconazole 0.12 mg/L
Caspofungin 0.25mg/L
Fusarium Chlamydosporum
Amphotericin B 0.5mg/L
Fluconazole 32 mg/L
Ketoconazole 1mg/L
Itraconazole 2mg/L
Voriconazole 0.5mg/L
Discussion: This case illustrates the benefits of new triazoles in
treating IFI, but highlights the drug interactions of the new tria-
zoles: voriconazole and posaconazole on treatment choices with a
review of the literature around these drug interactions.
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Respiratory Viral Infections in Renal Transplant Recipients
Mauro Jose Costa Salles1, Yvoty Alves dos Santos Sens2, Lucy
Villas Boas3, Clarisse Martins Machado3. 1Clinic of Infectious
Diseases, Department of Internal Medicine, Santa Casa de São
Paulo School of Medicine, São Paulo, Brazil; 2Nephrology,
Department of Internal Medicine, Santa Casa de São Paulo School
of Medicine, São Paulo, Brazil; 3Virology Laboratory, Institute of
Tropical Medicine, University of São Paulo (IMTSP-USP), São
Paulo, Brazil
Background: Solid organ transplant (SOT) recipients are partic-
ularly susceptible to community-acquired respiratory viruses and
they also appear more likely to experience pulmonary and extra-
pulmonary complications. Atypical clinical presentation caused by
influenza virus A and B or other virus are increasingly recognized
as a cause of morbidity including recipients rejection and chronic
allograft dysfunction.
Objectives: To determine the frequency and clinical aspects in-
cluding allograft complications of influenza A and B infection and
influenza-like illness caused by respiratory syncytial virus (RSV),
adenovirus, parainfluenza virus 1, 2 and 3 in renal transplant re-
cipients.
Methods: 434 nose-and-throat washes specimens were prospec-
tively collected from each patient every three weeks (5.78 samples
per patient) as well as clinical signs and symptoms of respiratory vi-
ral infections on 75 renal transplanted patients during six months.
Direct immunofluorescence (DIF) was the virological method used
for detecting respiratory virus.
Results: Influenza and flu-like symptoms were observed in 23.5%
of the subjects, including fever (temperature higher than 37.8°C),
nasal congestion, sore throat, cough, sneezing, headache, myal-
gia, weakness, fatigue and loss of appetite. Diagnosis of symp-
tomatic and asymptomatic patients with virus isolation collected
from nose-and-throat washes was able to detect only six episodes
of virus infection: 2 RSV, 2 parainfluenza, 1 influenza A and 1 in-
fluenza B. No significant difference was observed when serum cre-
atinine at six month was compared with baseline serum creatinine
(1.74±0.65, 1.84±0.55, p=0.312) and there were no serious com-
plications after virus infections during the six months period of
follow up.
Conclusion: Respiratory virus infections were not associated with
significant morbidity in renal transplant recipients.
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Characteristics of Transplant Recipients who Developed
Influenza in 2007-08 Despite Influenza Vaccination
Sherif Mossad. Department of Infectious Diseases, Cleveland
Clinic, Ohio, Cleveland, USA
Background: Influenza vaccination is less immunogenic in trans-
plant recipients than healthy people. Influenza A (H1N1) and B
circulating viruses during the 2007-2008 epidemic were different
from those contained in this season' s vaccine.
Objective: To describe clinical and immunological characteristics
of 15 transplant recipients who developed influenza despite in-
fluenza vaccination (group A), and compare them to 6 transplant
recipients who developed influenza in the absence of influenza
vaccination (group B), 13 transplant recipients who did not develop
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influenza (group C), and 8 healthy people who developed influenza
(group D.)
Methods: Case ascertainment through microbiology and electronic
medical records.
Results: Types of transplant: liver 3, heart 7, kidney 3, lung 8,
HSCT 8, kidney + pancreas 3, liver + kidney 1, liver + pancreas 1.
20 had influenza A, and 10 had influenza B (1 transplant recipi-
ent has both simultaneously.) Influenza occurred 1757 days (mean
[range 0-3850]) after transplant in group A, compared to 801 days
(range 20-3082) in group B. Influenza occurred 116 days (mean
[range 83-151] after vaccination in group A. There were no sta-
tistically significant differences in the incidence of fever, cough,
rhinorrhea, sore throat, malaise, shortness of breath, exposure to
contacts with similar symptoms, or presence of infiltrates on CXR
among groups A, B and D. Groups A and B were treated with os-
eltamivir significantly more frequently than Group D, [p=0.002].
Patients in group A were hospitalized more frequently than group
D [p=0.0002]. There were no statistically significant differences
in the incidence of pneumonia, ICU admission, mechanical ventila-
tion, or death among groups A, B and D. There were no statistically
significant differences between groups A, B and C in the incidence
of IgG < 600 mg/dL, immune function assay < 200 ng/mL, rejec-
tion (in SOT recipients) or GVHD (in HSCT recipients) in the preced-
ing 30 days. Patients in group A were significantly more likely to
have concomitant infections than group D [p=0.049], but not group
B.
Conclusions: Influenza vaccination did not alter clinical presenta-
tion of influenza in transplant recipients, or impact the incidence
of complications. Transplant recipients who developed influenza
despite influenza vaccination were not more immunosuppressed
than those who were vaccinated and did not develop influenza,
and were more likely to have concomitant infections than healthy
people.
35
Oral Candidiasis in Solid Organ Transplant Recipients
Anna Dongari-Bagtzoglou1, E. Ioannidou1, P. Dwivedi1, D. Hull2,
J. Burleson1. 1University of Connecticut, School of Dental
Medicine, Connecticut, USA; 2Hartford Hospital, Connecticut, USA
Background: Oral Candida carriage and/or infection have been re-
ported to be associated with a greater risk for esophagitis and
pneumonitis in renal and liver transplant recipients; however a sys-
tematic analysis of the oral Candida titers and species has not been
previously conducted. The objectives of this study were to deter-
mine the prevalence of oropharyngeal candidiasis and to define the
oral carrier status, Candida titers and species in this population.
Methods: 144 kidney and heart transplant subjects were recruited
from Hartford Hospital of whom 90 met the following criteria
and were included in analyses: 1. clinically stable; 2. at least
one year post transplant; 3. no history of antifungal or antibi-
otic use within the last 4 months. Control subjects (n=72) were
age- and sex-matched, systemically healthy individuals. Subjects
received an oral clinical examination. Swabs from the oral mucosa
and a standardized amount of unstimulated saliva were plated on
Chromagar® plates, and CFU/ml were calculated. Initial speciation
was based on colony color and was confirmed by standard germi-
nation and biotyping (carbohydrate assimilation) assays.
Results: Significantly more transplant (7.7%) than control (0%)
subjects had oral infection with C. albicans (p=0.004). A signif-
icantly higher (p=0.039) frequency of asymptomatic colonization
was noted in transplant recipients (51.1%) compared to healthy
controls (29.2%). In addition, the transplant group had signifi-
cantly higher Candida titers than the control group (p=0.04). There
was a significant positive association between diabetes and his-
tory of anti-fungals (p=0.039) and a significant negative associa-
tion between Cyclosporine treatment and history of anti-fungals
(p=0.0003). There were no statistically significant relationships be-
tween the dose or type of immunosuppressants and oral Candida
titers or infection. 13.3% of transplant carriers and 4.2% of the
control subjects were colonized by more than one species, a differ-
ence that was statistically significant (p=0.045). The most frequent
combination in transplant patients was C. albicans and C. glabrata.
C.glabrata was isolated in 7.8% of transplant patients and none
of the controls, a difference that was also statistically significant
(p=0.016).
Conclusions: Increased oral Candida infection and carriage titers
were found in solid organ transplant subjects who are at least one
year post-transplant. Although the majority of these subjects are
colonized by C. albicans, C.glabrata appears to emerge as the sec-
ond most prevalent species.
Supported by NIH/NIDCR DE016466 and MO1RR06192.
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De Novo T-Lymphocyte Responses against
Baculovirus-derived Recombinant Influenzavirus
Hemagglutinin Generated by a Naive Umbilical Cord Blood
Model of Dendritic Cell Vaccination
Amar Safdar, William K. Decker, Sufang Li, Elizabeth J. Shpall. M.
D. Anderson Cancer Center, Houston, Texas, USA
Background: Cordblood-derived (CB) is an important source of
mostly unprimed stem cells. We sought to generate CB-derived
dendritic cells (DC) immunotherapy against influenzavirus.
Methods: Recombinant hemagglutinin (rHA) of H1N1 was expressed
by vector pPSC12 cloned baculovirus in SF9 cells. Generation of Im-
mature DCs. Umbilical cord blood units discarded from the MDACC
CB bank was used after IRB approval. DC loading and maturation:
in the presence of GM-CSF and IL-4, immature dendritic cells were
loaded with rHA protein. Immature DCs were suspended at a con-
centration of 4x107 cells/ml, mixed with rHA and incubated for
10 minutes on ice in an electroporation cuvette. T-cell priming
and re-Stimulation: matured loaded DCs were incubated at a ratio
of 1:10 with autologous non-adherent PBMCs (typically 50% CD3+),
plus IL-12. ELISpot Assay was performed using standard method.
ELISpots for putative HA peptide epitopes were performed similarly
using 1x 105 - 2x 105 lymphocytes incubated overnight in 3.75 mi-
crograms/ml peptide. T-cell specificity and functionality was then
demonstrated by 51Cr CTL lysis.
Results: rHA-specific lymphocytes demonstrate identifiable HLA-
restriction. HA-primed lymphocytes (HLA DRbeta1*1503) from a
different CB demonstrated a nine-fold increase in statistically large
spots when restimulated with the DR15-262 epitope (p<0.00002).
These data suggest that 1 in 1,900 of the HA-specific T-cells were
DR15-262 restricted in a highly-specific fashion. Total ELISpot num-
bers (p<0.0002) and total IFN-gamma release (p<0.00004) be-
tween lymphocytes restimulated with DR15-262 and the control
peptide were statistically distinct as well. Incubation of peptide
DR15-262 in conjunction with HA-primed/DR15- lymphocytes or
in conjunction with adenoviral hexon-primed (irrelevant) lympho-
cytes did not demonstrate significant numbers of IFN-gamma spots.
51Cr CTL assay demonstrates the generation of HA-specific cyto-
toxic T-cell effectors. Naïve cord blood T-cells were stimulated
three times with rHA-loaded dendritic cells; specific lysis of rHA-
loaded autologous DC was double that of unloaded control targets
at an E:T ratio of 5:1 (p=0.05).
